TG Therapeutics, Inc. (NASDAQ:TGTX) Q2 2021 Earnings Conference Call August 2, 2021 8:30 AM ET Company Participants Jenna Bosco - Senior Vice President of Corporate Communications Mike Weiss - Executive Chairman & Chief Executive Officer Adam Waldman - Chief Commercialization Officer Sean Power - Chief Financial Officer Conference Call Participants Alethia Young - Cantor Fitzgerald Josh Schimmer - Evercore Eric Joseph - JPMorgan Chris Howerton - Jefferies Ed White - HC Wainwright Graig Suvannavejh - Goldman ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to TG THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 36-3898269 (State or other jurisdiction of incorporation or or ...

TG Therapeutics, Inc. (NASDAQ:TGTX) Q1 2021 Earnings Conference Call May 10, 2021 8:30 AM ET Company Participants Jenna Bosco - Senior Vice President of Corporate Communications Sean Power - Chief Financial Officer Mike Weiss - Executive Chairman and Chief Executive Officer Adam Waldman - Chief Commercialization Officer Conference Call Participants Alethia Young - Cantor Fitzgerald Chris Howerton - Jefferies Josh Schimmer - Evercore Eric Joseph - JPMorgan Ed White - HC Wainwright Matt Kaplan - Ladenburg Tha ...

TG Therapeutics ULTIMATE I & II Data Preview Call April 2021 Forward-Looking Safe Harbor Statement ▪ This is presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the Company's current beliefs, expectations and assumptions. These statements include but are not limited to statements regarding the future of the Company's business, our future plans and strategies, clinical trial results, and regulatory filings and approvals. T ...

TG Therapeutics Inc. (NASDAQ:TGTX) Q4 2020 Earnings Conference Call March 2, 2020 8:30 AM ET Company Participants Jenna Bosco – Senior Vice President of Corporate Communications Sean Power – Chief Financial Officer Michael Weiss – Executive Chairman and Chief Executive Officer Adam Waldman – Chief Commercialization Officer Conference Call Participants Alethia Young – Cantor Fitzgerald Roger Song – Jefferies Ed White – HC Wainwright Matt Kaplan – Ladenburg Thalmann Mayank Mamtani – B. Riley Securities Operat ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________. Commission File Number 1-32639 TG THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 36-3898269 (Stat ...

J.P. Morgan 39th Annual Healthcare Conference January 2021 Forward Looking Safe Harbor Statement 2 | --- | --- | |-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32639 TG THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 36-3898269 (State or othe ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32639 TG THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 36-3898269 (State or other jur ...

TG Therapeutics Inc. (NASDAQ:TGTX) Q2 2020 Earnings Conference Call August 10, 2020 8:30 AM ET Company Participants Michael Weiss - Executive Chairman, President, Chief Executive Officer Sean Power - Chief Financial Officer Jenna Bosco - Senior Vice President, Corporate Communications Conference Call Participants Josh Schimmer - Evercore ISI Ed White - HC Wainwright Matt Kaplan - Ladenburg Roger Song - Jefferies Operator Hello and welcome to the TG Therapeutics second quarter 2020 earnings conference call. ...